Anti-inflammatory effects of kaempferol, myricetin, fisetin and ibuprofen in neonatal rats
Abstract
Purpose: To investigate the anti-inflammatory effects of kaempferol, myricetin, fisetin and ibuprofen in rat pups.
Methods: The expression levels of cyclooxygenase (COX)-1, COX-2 and tumour necrosis factor-α (TNF-α) were determined by western blotting; the inhibition of these proteins by plant compounds was evaluated. In addition, a computational simulation of the molecular interactions of the compounds at the active sites of the proteins was performed using a molecular docking approach. Absorption, distribution, metabolism and excretion (ADME) and toxicity analysis of the plant compounds was also performed.
Results: Kaempferol, myricetin and fisetin inhibited the activities of COX-1, COX-2 and TNF-α by 70–88%. The computational simulation revealed the molecular interactions of these compounds at the active sites of COX-1, COX-2 and TNF-α. ADME and toxicity analysis demonstrated that the three plant compounds were safe.
Conclusion: The data obtained indicate that myricetin, kaempferol and fisetin exert anti-inflammatory effects in neonatal rats, with fewer side effects than those of ibuprofen.
Keywords: Non-steroidal anti-inflammatory drugs, Cyclooxygenase-1, Cyclooxygenase-2, Tumour necrosis factor-α
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
